FDA
- Status: approved
Combination of low ICS and montelukast (Combination of low ICS and montelukast) regulatory status in United States.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA has authorised it.
Ajou University School of Medicine is the originator. The local marketing authorisation holder may differ — check the official source linked above.